Clinical Trial

Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes

Study acronym: BIOMARKERS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients living with diabetes mellitus have double the risk of kidney failure compared to patients without diabetes following use of dye in many x-rays and procedures to diagnose and treat narrowing of the arteries (blood vessels) in the heart that can lead to angina or a heart attack. Heart disease is the commonest cause of death in patients with diabetes. People with diabetes are more likely to need these tests/treatments. By identifying those at greater risk of kidney complications we may be able to make these tests/treatments safer and offer them to more patients with diabetes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2009-07-28; most recent amendment 2024-12-05.
Trial Details
NCT Number NCT00948116
Lead Sponsor Barts & The London NHS Trust
Conditions Diabetes Mellitus, Renal Impairment
Enrollment 250 participants
Start Date 2009-06-24
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-10